Energy Technology Meet inaugurated in Goa, Highlights India's Energy Security Priorities (See 'Corp Brief') Discussions must lead to practical actions that cities can adopt: MoS (See 'Corp Brief') CARA organises Regional Consultative Workshop to expand Adoption of Children with Special Needs (See 'Corp Brief') ICAR-MGIFRI promotes Soil Health, Balanced Fertilisation and Sustainable Orchard Management (See 'Corp Brief') IPR - If well-known pharmaceutical mark with established goodwill & continuous use is sought to be diluted by subsequent user adopting coined expression sharing dominant prefix, case calls for interim injunction: HC (See 'Legal Desk') Bhupender Yadav emphasizes importance of Science-based Biodiversity Governance (See 'Corp Brief') PM Vishwakarma Artisans showcase Traditional Crafts at BRICS Cultural Bazar (See 'Corp Brief') Industrial Settlements benefit Over 10,900 Bihar Gramin Bank Employees (See 'Corp Brief') Startup Credit Guarantees reach Rs 1,662 Crore (See 'Corp Brief') IPR - Converting passing off action into infringement claim post-registration does not change basic structure of suit: HC (See 'Legal Desk') Nadda leads Integrity Pledge Ceremony at Ministry of Health and Family Welfare (See 'Corp Brief') RM calls for 'Aatmanirbharta 2.0', next leap in defence self-reliance, at SWAVLAMBAN 2026 (See 'Corp Brief') IBC - Admission u/s 7 IBC requires summary finding of debt & default above statutory threshold, and not exact reconciliation or forensic reconciliation of accounts: SC (See 'Legal Desk') MoRTH to organise 'Transport Mela' under PARIVARTAN Scheme in Delhi-NCR (See 'Corp Brief') NCB launches 'Operation Trident', with 38 teams striking 38 locations (See 'Corp Brief') NIFTEM-K hosts India's First AI × Food Tech Hackathon, 'Hack the Fork' (See 'Corp Brief') Misc - Administrator could neither assume RBI's write-down power at point of non-viability nor exercise it after reconstruction scheme took effect: SC (See 'Legal Desk') GeM promotes 'The AABHAR Collection' to showcase India's Cultural Heritage (See 'Corp Brief') National Conclave 2026: Technical sessions outline reforms for future-ready cities (See 'Corp Brief') PM's appeal has given a new identity to Khadi: KVIC Chairman (See 'Corp Brief') SARFAESI - Secured creditor stepping into shoes of borrower/lessee cannot claim rights superior to those of original lessee: HC (See 'Legal Desk') Three-day event 'India Chem-2026' concludes in Mumbai (See 'Corp Brief') Agricultural Biological Resources generate ABS Benefits for Biodiversity (See 'Corp Brief') BHASHINI Division showcases Multilingual AI Solutions for Accessible Research at IIT Delhi (See 'Corp Brief') Capital Market - Sec 12A of Commercial Courts Act is mandatory and strict condition precedent for maintaining commercial suit where no urgent interim relief is contemplated: HC (See 'Legal Desk') Fisheries Investors & Exporters Conclave 2026 to boost Investment and Exports from Inland Fisheries (See 'Corp Brief') India's First Maritime NBFC SMFCL scales up with Rs 5,107 Crs disbursed (See 'Corp Brief') India advances Agrivoltaics Cooperation for Global South (See 'Corp Brief') RTI - Information regarding public orders & ongoing court proceedings is already accessible in public domain - falls outside disclosure obligations of public authority under statute: SEBI (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT)

Print

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.